Formycon AG
FYB | F
Overview
Corporate Details
- ISIN(s):
- DE000A1EWVY8
- LEI:
- 39120005TZ76GQOY8Z19
- Country:
- Germany
- Address:
- Fraunhoferstraße 15, 82152 Planegg
- Website:
- https://www.formycon.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Formycon AG is a leading, independent, commercial-stage developer of biosimilars, which are high-quality, cost-effective follow-on products to off-patent biopharmaceutical medicines. As a specialized 'pure-play' biosimilar company, its activities are focused on the development of treatments in ophthalmology, immunology, and other key chronic diseases. Formycon's mission is to improve global patient access to safe and affordable biologic medicines, contributing to sustainable healthcare systems.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Formycon AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-13 06:30 |
Earnings Release
Formycon confirms full-year guidance following business development in line wit…
|
English | 29.9 KB | |
| 2025-08-13 00:00 |
Interim Report
Half-yearly financial report 2025
|
English | 8.5 MB | |
| 2025-07-31 13:49 |
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.4 KB | |
| 2025-07-30 06:30 |
Regulatory News Service
Formycon invites to conference call on 2025 half-year results and announces par…
|
English | 13.6 KB | |
| 2025-07-16 07:20 |
Report Publication Announcement
|
English | 3.9 KB | |
| 2025-07-10 06:30 |
Legal Proceedings Report
Formycon successfully completes patient enrollment for the clinical developmen…
|
English | 15.2 KB | |
| 2025-07-01 13:15 |
M&A Activity
Bio Usawa becomes partner for the commercialization of FYB201/ BioUcentaTM (ran…
|
English | 14.8 KB | |
| 2025-06-27 15:51 |
Capital/Financing Update
Formycon increases bond volume following oversubscription Bond 2025/2029 with …
|
English | 14.9 KB | |
| 2025-06-26 06:30 |
Business and Financial Review
Teva becomes secondary commercialization partner for Formycon's Stelara biosimi…
|
English | 15.6 KB | |
| 2025-06-25 06:30 |
Regulatory News Service
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization part…
|
English | 17.0 KB | |
| 2025-06-24 19:50 |
Capital/Financing Update
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscriptio…
|
English | 19.6 KB | |
| 2025-06-20 09:00 |
Capital/Financing Update
Formycon bond 2025/2029: Public subscription now also possible via Deutsche Bor…
|
English | 19.8 KB | |
| 2025-06-18 16:43 |
Post-Annual General Meeting Information
Ordinary Annual General Meeting of Formycon AG approves all proposed resolution…
|
English | 12.9 KB | |
| 2025-06-18 06:25 |
Capital/Financing Update
Formycon AG: Subscription period for 2025/2029 corporate bond has started
|
English | 20.5 KB | |
| 2025-06-17 08:01 |
Capital/Financing Update
Formycon plans public corporate bond issuance to support next growth phase with…
|
English | 21.3 KB |
Automate Your Workflow. Get a real-time feed of all Formycon AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Formycon AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-21 | Seidl, Dr. Andreas | Board | Buy | None | 4,800.00 EUR |
| 2024-04-29 | Mikulcik, Dr. Marc | Close relation | Buy | None | 48,000.00 EUR |
| 2024-04-24 | Glombitza, Dr. Stefan | Board | Buy | None | 97,444.00 EUR |
